Loading
Eryaspase packed a leukaemia enzyme into red blood cells to starve pancreatic cancer of an amino acid; the phase 3 TRYbeCA-1 trial missed its survival goal.
Erytech Pharma, now part of Phaxiam, built eryaspase for tumours that cannot make their own asparagine. A randomised phase 2 in second-line pancreatic cancer had shown longer survival, which led to the phase 3 TRYbeCA-1 trial of eryaspase with chemotherapy against chemotherapy alone in the second line.
TRYbeCA-1 reported in 2021: overall survival was not significantly improved, and the pancreatic programme ended.
Depletes circulating asparagine, an amino acid that pancreatic tumours with low asparagine synthetase cannot make, while the red-cell shell protects the enzyme and reduces toxicity.
1.Eryaspase slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Eryaspase" OR ABSTRACT:"Eryaspase" OR TITLE:"GRASPA" OR ABSTRACT:"GRASPA" OR TITLE:"L-asparaginase encapsulated in red blood cells" OR ABSTRACT:"L-asparaginase encapsulated in red blood cells") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Eryaspase, not a curated reading list.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.